ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

HCM HUTCHMED China Limited

18.675
-0.315 (-1.66%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
HUTCHMED China Limited HCM NASDAQ Certificado de Depósito
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.315 -1.66% 18.675 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
18.99 17.46 18.99 18.16 18.99
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
26/4/202407:30GLOBEHUTCHMED Announces Positive CHMP Opinion for Fruquintinib in..
05/4/202403:30GLOBEHUTCHMED Highlights Data to be Presented at..
01/4/202423:30GLOBEHUTCHMED and Innovent Jointly Announce NDA Acceptance in..
27/3/202419:00GLOBEHUTCHMED Announces Savolitinib sNDA Accepted in China for..
21/3/202419:00GLOBEHUTCHMED Initiates Registration Stage of the ESLIM-02 Phase..
05/3/202405:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/2/202405:47EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/2/202405:40EDGAR2Form 20-F - Annual and transition report of foreign private..
28/2/202405:30GLOBEHUTCHMED Reports 2023 Full Year Results and Provides..
07/2/202405:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/2/202418:00GLOBEHUTCHMED Highlights Presentation of Phase III Data on..
02/2/202405:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/2/202402:30GLOBEHUTCHMED Announces that Inmagene Exercises Option to License..
01/2/202405:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/2/202402:30GLOBEHUTCHMED to Announce 2023 Final Results
30/1/202405:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/1/202422:53GLOBEHUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval..
11/1/202405:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/1/202401:00RNSNONHutchmed (China) Limited Sovleplenib NDA Granted Priority..
10/1/202418:00GLOBEHUTCHMED Announces NDA Acceptance in China for Sovleplenib..
29/12/202305:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/12/202305:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/12/202305:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/12/202301:00RNSNONHutchmed (China) Limited Completed Enrollment of Phase..
12/12/202322:30GLOBEHUTCHMED Announces Continued Inclusion of ELUNATE®..
12/12/202318:00GLOBEHUTCHMED Announces that it has Completed Enrollment of a..
07/12/202305:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/12/202305:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/12/202301:00RNSNONHutchmed (China) Limited Clinical Data to be Presented at..
30/11/202318:00GLOBEHUTCHMED Highlights Clinical Data to be Presented at 2023..
30/11/202305:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/11/202307:35GLOBEDeutsche Bank ADR Investor Conference: Presentations Now..
09/11/202305:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/11/202318:11GLOBEHUTCHMED Announces that Takeda Receives U.S. FDA Approval of..
01/11/202307:35GLOBEInternational companies to host live webcasts at Deutsche..
24/10/202305:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/10/202305:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/10/202303:30GLOBEHUTCHMED Highlights Clinical Data to be Presented at..
29/9/202305:20EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/9/202303:30GLOBEHUTCHMED Announces Submission of New Drug Application for..
14/9/202305:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/9/202305:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/9/202303:30GLOBEHUTCHMED Highlights Presentation of Results from the Phase..
12/9/202301:00RNSNONHutchmed (China) Limited Patient Enrollment Completed for..
11/9/202319:00GLOBEHUTCHMED Completes Patient Enrollment of a Bridging Study of..
31/8/202305:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/8/202305:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/8/202301:00RNSNONHutchmed (China) Limited BTD in China for Savolitinib for..
28/8/202319:00GLOBEHUTCHMED Receives Breakthrough Therapy Designation in China..
21/8/202305:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..

Su Consulta Reciente

Delayed Upgrade Clock